Clinical Trial Update: Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating capmatinib in Indian patients with MET exon 14 skipping mutation–positive advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Carcinoma | Phase 4 | Status: COMPLETED